Melioidosis and the kidney

Nephrology

Volumn 18, Issue 3, 2013, Pages 169-175

  Jabbar, Zulfikar ^a,b   Currie, Bart J ^a,c  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

bioterrorism; Burkholderia pseudomallei; chronic kidney disease; immune suppression; melioidosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CEFTAZIDIME; COTRIMOXAZOLE; CYCLOSPORIN; MEROPENEM; METHOTREXATE; PREDNISOLONE;

ABDOMINAL ABSCESS; ACUTE KIDNEY FAILURE; AFRICA; AGRICULTURAL WORKER; ALCOHOL CONSUMPTION; ANTIMICROBIAL THERAPY; AUSTRALIA; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL TRANSMISSION; CHINA; CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; ERADICATION THERAPY; GARDENING; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INCUBATION TIME; INDIA; INFECTION RATE; INHALATION; INNATE IMMUNITY; KIDNEY DISEASE; KOREA; LANDSCAPING; MACROPHAGE FUNCTION; MADAGASCAR; MAURITIUS; MELIOIDOSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OCCUPATIONAL EXPOSURE; OSTEOMYELITIS; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; SEROLOGY; SKIN INFECTION; SOUTHEAST ASIA; SRI LANKA; TAIWAN; THAILAND; THROAT CULTURE; UROGENITAL TRACT INFECTION; WATER CONTAMINATION; WESTERN HEMISPHERE;

ACUTE KIDNEY INJURY; ANTI-INFECTIVE AGENTS; BURKHOLDERIA PSEUDOMALLEI; COMORBIDITY; ENDEMIC DISEASES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELIOIDOSIS; PROGNOSIS; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84874455479     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12024     Document Type: Review

References (55)

1. Whitmore A, Krishnaswami CS,. An account of the discovery of a hitherto underscribed infective disease occurring among the population of Rangoon. Ind. Med. Gaz. 1912; 47: 262-267.
2. Cheng AC, Currie BJ,. Melioidosis: Epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 2005; 18: 383-416. [Erratum, Clin. Microbiol. Rev. 2007; 20: 533.].
3. Currie BJ,. Melioidosis: An important cause of pneumonia in residents of and travellers returned from endemic regions. Eur. Respir. J. 2003; 22: 542-550.
4. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 2010; 82: 1113-1117.
5. Wiersinga WJ, Currie BJ, Peacock SJ,. Melioidosis. N. Engl. J. Med. 2012; 367: 1035-1044.
6. Centers for Disease Control and Prevention. Biological and chemical terrorism: Strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR 2000; 49: 1-14.
7. Currie BJ, Mayo M, Anstey N, Donohoe P, Haase A, Kemp DJ,. A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am. J. Trop. Med. Hyg. 2001; 65: 77-179.
8. Inglis TJ, Garrow SC, Adams C, Henderson M, Mayo M, Currie BJ,. Acute melioidosis outbreak in Western Australia. Epidemiol. Infect. 1999; 123: 437-443.
9. Ralph A, McBride J, Currie BJ,. Transmission of Burkholderia pseudomallei via breast milk in northern Australia. Pediatr. Infect. Dis. J. 2004; 23: 1169-1171.
10. Abbink FC, Orendi JM, de, Beaufort AJ,. Mother-to-child transmission of Burkholderia pseudomallei. N. Engl. J. Med. 2001; 344: 1171-1172.
11. Currie BJ, Jacups SP,. Intensity of rainfall and severity of melioidosis, Australia. Emerg. Infect. Dis. 2003; 9: 1538-1542.
12. Currie BJ, Ward L, Cheng AC,. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl. Trop. Dis. 2010; 4 (11): e900.
13. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin. Infect. Dis. 1999; 29: 408-413.
14. Heng BH, Goh KT, Yap EH, Loh H, Yeo M,. Epidemiological surveillance of melioidosis in Singapore. Ann. Acad. Med. Singapore 1998; 27: 478-484.
15. Currie BJ, Jacups SP, Cheng AC, et al. Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop. Med. Int. Health 2004; 9: 1167-1174.
16. Jones AL, Beveridge TJ, Woods DE,. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 1996; 64: 782-790.
17. Heinzelmann M, Mercer-Jones MA, Passmore JC,. Neutrophils and renal failure. Am. J. Kidney Dis. 1999; 34: 384-399.
18. Iida TK, Umezawa K, Tanaka Y, Nakazawa KH, Satoh T,. Polymorphonuclear cells in chronic hemodialysis patients have intact phagocytotic and impaired bactericidal activities. Nephron 1997; 75: 41-47.
19. Malczewski AB, Oman KM, Norton RE, Ketheesan N,. Clinical presentation of melioidosis in Queensland, Australia. Trans. R. Soc. Trop. Med. Hyg. 2005; 99: 856-860.
20. Varughese S, Mohapatra A, Sahni R, Balaji V, Tamilarasi V,. Renal allograft recipient with melioidosis of the urinary tract. Transpl. Infect. Dis. 2011; 13: 95-96.
21. John GT, Ahmed I, Jacob CK, Jesudason MV, Lalitha MK,. Melioidosis in a renal transplant recipient. Transplantation 2003; 76: 262.
22. Chierakul WA, Rajanuwong V, Wuthiekanun N, et al. The changing pattern of bloodstream infections associated with the rise in HIV prevalence in northeastern Thailand. Trans. R. Soc. Trop. Med. Hyg. 2004; 98: 678-686.
23. Chierakul W, Wuthiekanun V, Chaowagul W, et al. Short report: Disease severity and outcome of melioidosis in HIV coinfected individuals. Am. J. Trop. Med. Hyg. 2005; 73: 1165-1166.
24. Currie BJ, Fisher DA, Anstey NM, Jacups SP,. Melioidosis: Acute and chronic disease, relapse and re-Activation. Trans. R. Soc. Trop. Med. Hyg. 2000; 94: 301-304.
25. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G,. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol. 2005; 43: 970-972.
26. Puthucheary SD, Parasakthi N, Lee MK,. Septicaemic melioidosis: A review of 50 cases from Malaysia. Trans. R. Soc. Trop. Med. Hyg. 1992; 86: 683-685.
27. Dance DA, Davis TM, Wattanagoon Y, et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J. Infect. Dis. 1989; 159: 654-660.
28. White NJ,. Melioidosis. Lancet 2003; 361: 1715-1722.
29. Chaowagul W, Suputtamongkol Y, Dance DAB, Rajchanuvong A, Pattara-Arechachai J, White NJ,. Relapse in melioidosis: Incidence and risk factors. J. Infect. Dis. 1993; 168: 1181-1185.
30. Limmathurotsakul D, Chaowagul W, Chierakul W, et al. Risk factors for recurrent melioidosis in northeast Thailand. Clin. Infect. Dis. 2006; 43: 979-986.
31. Susaengrat W, Dhiensiri T, Sinavatana P, Sitprija V,. Renal failure in melioidosis. Nephron 1987; 46: 167-169.
32. Northfield J, Whitty CJM, Macphee IAM,. Burkholderia pseudomallei infection, or melioidosis, and nephrotic syndrome. Nephrol. Dial. Transplant. 2002; 17: 137-139.
33. Walsh AL, Smith MD, Wuthiekanun V, et al. Immunofluorescence microscopy for the rapid diagnosis of melioidosis. J. Clin. Pathol. 1994; 47: 377-379.
34. Cheng AC, O'brien M, Freeman K, Lum G, Currie BJ,. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am. J. Trop. Med. Hyg. 2006; 74: 330.
35. Appassakij H, Silpapojakul KR, Wansit R, Pornpatkul M,. Diagnostic value of the indirect hemagglutination test for melioidosis in an endemic area. Am. J. Trop. Med. Hyg. 1990; 42: 248.
36. Richardson LJ, Kaestli M, Mayo M, et al. Towards a rapid molecular diagnostic for melioidosis: Comparison of DNA extraction methods from clinical specimens. J. Microbiol. Methods 2012; 88: 179-181.
37. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2: 697.
38. Smith MD, Wuthiekanun V, Walsh AL, White NJ,. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J. Antimicrob. Chemother. 1996; 37: 611.
39. Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 1999; 29: 381.
40. Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob. Agents Chemother. 2004; 48: 1763.
41. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure, 5th edn. Philadelphia: American College of Physicians, 2007.
42. Matzke GR, Aronoff GR, Atkinson AJ, et al. Drug dosing considerations in patients with acute and chronic kidney disease-A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80 (11): 1122-1137.
43. Therapeutic Guidelines. Renal impairment and antimicrobial dosing (Appendix 2.5). eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited, 2012. [Cited 22 October 2012.] Available from URL: http://online.tg. org.au/
44. Hirata S, Kadowaki D,. Appropriate drug dosing in patients receiving peritoneal dialysis. Contrib. Nephrol. 2012; 177: 30-37. [Epub 2012 May 8]
45. Kim K, Hwang YH, Ro H, et al. Pharmacokinetic profiles of ceftazidime after intravenous administration in patients undergoing automated peritoneal dialysis. Antimicrob. Agents Chemother. 2011; 55 (6): 2523-2527.
46. Sarovich DS, Price EP, Von Schulze AT, et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PloS ONE 2012; 7 (2): e30789.
47. Chantratita N, Rholl DA, Sim B, et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc. Natl Acad. Sci. U.S.A. 2011; 108 (41): 17165-17170.
48. Kung CT, Lee CH, Li CJ, Lu HI, Ko SF, Liu JW,. Development of ceftazidime resistance in Burkholderia pseudomallei in a patient experiencing melioidosis with mediastinal lymphadenitis. Ann. Acad. Med. Singapore 2010; 39 (12): 945-947.
49. Behera B, Prasad Babu T, Kamalesh A, Reddy G,. Ceftazidime resistance in Burkholderia pseudomallei: First report from India. Asian Pac. J. Trop. Med. 2012; 5 (4): 329-330.
50. Wuthiekanun V, Amornchai P, Saiprom N, et al. Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand. Antimicrob. Agents Chemother. 2011; 55: 5388-5391.
51. Wuthiekanun V, Cheng AC, Chierakul W, et al. Trimethoprim/ sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother. 2005; 55: 1029-1031.
52. Cheng AC, Stephens DP, Anstey NM, Currie BJ,. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin. Infect. Dis. 2004; 38: 32.
53. Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin. Infect. Dis. 2007; 45: 308.
54. Peacock SJ, Limmathurotsakul D, Lubell Y, et al. Melioidosis vaccines: A systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PloS Negl. Trop. Dis. 2012; 6: e1488.
55. NT Centre for disease control. Melioidosis. 2012. [Cited 29 October 2012.] Available from URL: http://www.health.nt.gov.au/library/%20scripts/ objectifyMedia.aspx?file=pdf/43/46.pdf&siteID=1&strle=%20Melioidosis.pdf